Therapeutic Advances in Medical Oncology
Journal Highlights
- Gold open access journal – all articles are made freely available online immediately upon publication
- Rigorous peer review
- Listed in PubMed and indexed in Web of Science, Science Citation Index Expanded (SCIE) and Scopus
- Internationally renown, expert Editorial Board and panel of Associate Editors
- A leading gold open access journal in oncology
- Over 500,000 full-text article views annually
Therapeutic Advances in Medical Oncology (TAM) is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies in the medical treatment of cancer. Please see the Aims and Scope tab for further information.
Diversity, Equity and Inclusion Statement
Therapeutic Advances in Medical Oncology (TAM) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the oncology community.
Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.
We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.
We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.
Submission information
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access article processing charge (APC) information
Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons licence.
The APC for this journal is currently $3200 USD. The article processing charge for Plain Language Summary is $5000 USD.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
This journal flipped to open access on September 1, 2016.
Contact
Therapeutic Advances in Medical Oncology (TAMO) is Sage’s flagship open access oncology journal dedicated to publishing high-quality clinical research and clinically relevant translational studies that advance the medical treatment of cancer. TAMO is recognized for publishing rigorously peer-reviewed and impactful research in the field of oncology. TAMO serves as a premier online forum for the rapid dissemination of original research and reviews that directly inform patient care and therapeutic strategies. The journal maintains a strong clinical and pharmacological focus, covering systemic therapies (chemotherapy, targeted agents, immunotherapy, hormonal treatments), radiotherapy, and combination approaches relevant to the practice of medical oncology.
We welcome submissions addressing both solid tumors and hematologic malignancies; however, benign tumors are outside the scope of the journal. Our primary audience includes clinicians and researchers seeking the latest evidence to improve patient outcomes.
Topics include, but are not limited to:
-Clinical Studies: Phase I-IV clinical trials, observational studies, real-world evidence, outcomes research, and comparative effectiveness studies. For clinical trials, Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
-Translational Research: Studies integrating clinical data with laboratory analyses (e.g., biomarkers, molecular profiling, pharmacokinetics/pharmacodynamics in patient samples) that demonstrate clear, near-term clinical relevance.
-Novel Therapeutic Approaches: Investigations of new drugs, biologics, therapeutic combinations, and radiotherapy techniques.
-Treatment Optimization: Research on efficacy, safety, toxicity management, and resistance mechanisms supported by clinical data.
-Precision Oncology: Biomarker-driven therapies and personalized medicine strategies implemented in clinical settings.
TAMO focuses on research involving human subjects or human-derived data/samples with immediate clinical implications. While translational studies are welcome, purely preclinical research, including basic laboratory investigations using only cell lines or animal models without direct clinical correlation, is outside the journal’s scope.
This journal is a member of the Committee on Publication Ethics (COPE).
| Lingling Tian | SAGE Publishing, Shanghai, China |
| Rodabe Amaria, MD | Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| Carlos Barrios, MD | Latin American Cooperative Oncology Group (LACOG), Oncoclínicas, Porto Alegre, Brazil |
| Giuseppe Curigliano, MD, PhD | Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy |
| Ian D. Davis | Monash University, Australia |
| Karim Fizazi, MD, PhD | University of Paris Saclay, France |
| Nadia Harbeck, MD, PhD | University of Munich, Germany |
| Sara Hurvitz, MD, FACP | David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, UCLA, CA, USA |
| Swaminathan Iyer, MD | MD Anderson Cancer Center, USA |
| Jonathan Ledermann, MBBS, MRCP, MD, FRCP | UCL Cancer Institute, University College London, UK |
| Nancy Y Lee, MD, FASTRO | Memorial Sloan Kettering Cancer Center, United States |
| Natasha Leighl, MD | Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada |
| Javier Martin-Broto, MD, PhD, ASCO, ESMO | Fundacion Jimenez Diaz University Hospital, Madrid, Spain |
| Keunchil Park, MD, PhD | Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, TX, USA |
| Gerald Prager, MD, PhD | Department of Medical Oncology, Medical University of Vienna (MUV) and Comprehensive Cancer Center Vienna, Austria |
| Liang Qiao, PhD, EASL, ASSCR, CRA | The University of Sydney, Westmead, Australia |
| Rachel Riechelmann, MD, PhD, ESMO, SLAGO, LACOG | Clinical Oncology Department, AC Camargo Cancer Center, Sao Paulo, Brazil |
| Rachna Shroff, MD, MS, FASCO | University of Arizona Cancer Center, University of Arizona College of Medicine – Tucson, AZ, USA |
| Ross Soo, MBBS, FRACP, FAMS, ASCO, IASLC, SSO | Department of Haematology-Oncology, National University Cancer Institute, Singapore |
| Srikala Sridhar, MD, CCTG | Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada |
| Raghav Sundar, MD, PhD | Yale School of Medicine, Yale University, USA |
| David Tan, PhD | American University of the Middle East, Kuwait and Macquarie University, Australia |
| Hanneke van Laarhoven, MD, ESMO | Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands |
| Evandro De Azambuja, MD, PhD | Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Belgium |
| Alessandra Gennari, MD, PhD | Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy |
| Kevin Kalinsky, MD, MS | Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, USA |
| Sung-Bae Kim, MD, PhD | Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea |
| Bora Lim, MD | Division of Cancer Medicine, The UT MD Anderson Cancer Center, TX, USA |
| Miguel Martín, MD, PhD | Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain |
| Nicholas McAndrew, MD, MSCE | Division of Hematology/Oncology, UCLA David Geffen School of Medicine, CA, USA |
| Yeon Hee Park, MD, PhD | Sungkyunkwan University School of Medicine, Seoul, Korea |
| Sagar Sardesai, MD, MPH | Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, OH, USA |
| Cristina Saura, MD, PhD | Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Spain |
| Priyanka Sharma, MD | Division of Medical Oncology, University of Kansas Medical Center and Drug Discovery, Delivery and Experimental Therapeutics program, University of Kansas Cancer Center, USA |
| Laura Spring, MD | Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA |
| Paolo Tarantino, MD | Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA |
| Sara Tolaney, MD, MPH | Division of Breast Oncology, Dana-Farber Cancer Institute, MA, USA & Harvard Medical School, MA, USA |
| Neelima Vidula, MD | Massachusetts General Hospital Boston, USA |
| Nikhil Wagle, MD | Genentech, South San Francisco, California, USA |
| Seth Wander, MD, PhD | Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA |
| Yoon-Sim Yap, MBBS, FRACP, PhD | National Cancer Centre Singapore, Duke-National University Singapore (Duke-NUS), Singapore |
| Enrico Franceschi, MD | Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy |
| Maria-Magdalena Georgescu, MD, PhD, MSc | NeuroMarkers, Houston, Texas, USA |
| Patrick Roth, MD | University Hospital Zurich, Department of Neurology and Brain Tumor Center Zurich, Switzerland |
| Giulia Baciarello, MD | Department of Medical Oncology, S. Camillo-Forlanini Hospitals, Rome, Italy |
| Elena Castro, MD, PhD | Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain |
| Kim N Chi, MD, FRCPC | University of British Columbia, Vancouver, BC, Canada |
| Toni K Choueiri, MD | Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA |
| Maria De Santis, MD | Charité University Hospital, Germany |
| Tim Eisen, PhD | Cambridge University, Cambridge, UK |
| Matt Galsky | Tisch Cancer Institute, USA |
| Lisa G. Horvath, MBBS, FRACP, PhD | Department of Medical Oncology, Chris O’Brien Lifehouse, University of Sydney, Sydney, Australia |
| Maha Hussain, MD, FACP, FASCO | Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, USA |
| Lorena Incorvaia, MD, PhD | Department of Biomedicine, Neuroscience and Advanced Diagnostic (BiND), Section of Medical Oncology, University of Palermo, Italy |
| Ravindran Kanesvaran, MD, MRCP, FAMS | Division of Medical Oncology, National Cancer Centre Singapore, Singapore |
| Alicia Morgans, MD, MPH | Harvard Medical School/ Survivorship Program, Dana-Farber Cancer Institute, Boston, MA |
| Kent Mouw, MD, PhD | Dana-Farber Cancer Institute/Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, USA |
| Jones Nauseef, MD, PhD | Convergent Therapeutics, Boston, MA; Weill Cornell Medicine, New York, NY, USA |
| Anna Patrikidou, MD, PhD | Department of Cancer Medicine, Gustave Roussy Institute, University of Paris Saclay, Villejuif, France |
| David Quinn, MBBS (Hons I), PhD, FRACP, FACP | University of Minnesota, USA |
| Marniza Saad, FRCR, MBBCh | Department of Clinical Oncology, Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia |
| Scott Tagawa, MD, MS, FACP, FASCO | Weill Cornell Medicine, New York, NY, USA |
| Ben Tran, MBBS | Peter MacCallum Cancer Centre, Australia |
| Thomas Aparicio, MD, PhD | Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, Gastroenterology and Digestive Oncology Department, Université de Paris Cité, Paris, France |
| Dirk Arnold, MD | Asklepios Tumorzentrum Hamburg, AK Altona |
| Eishi Baba, MD, PhD | Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Japan |
| Irit Ben-Aharon, MD, PhD | Fishman Oncology Center, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel |
| Sakti Chakrabarti, MD | Division of Hematology and Medical Oncology at UH Seidman Cancer Center, Case Comprehensive Cancer Center, and Case Western Reserve University, OH, USA |
| Stephen Chan, MBBS, MRCP, FHKCP, FHKAM, FRCP, FRCP | The Chinese University of Hong Kong, Hong Kong |
| Yun Dai, MD | Department of Gastroenterology, Peking University First Hospital, Beijing, China |
| Richard Finn, MD | Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, CA, USA |
| Aysegül Ilhan-Mutlu, MD, PhD | Division of Oncology, Department of Medicine I, Director of Gastroesophageal Tumors Unit, Medical University of Vienna, Austria |
| Yumin Li, PhD | Lanzhou University and Lanzhou University Second Hospital, China |
| Jonathan Loree, MD, MS, FRCPC | Division of Medical Oncology, BC Cancer, Vancouver, Canada |
| Teresa Macarulla, MD, PhD | Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain |
| Matthew Ng, PhD | National Cancer Centre Singapore, Singapore |
| Radka Obermannová, MD, PhD | Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk University, Masaryk Memorial Cancer Institute, Czech Republic |
| Lorenza Rimassa, MD | Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy |
| Olivier Rosmorduc, MD, PhD | Hepato-Biliary Center, Paul Brousse Hospital, Paris Saclay University, Villejuif, France |
| Thomas Seufferlein, MD, PhD | Department of Internal Medicine 1, University Hospital Ulm, Ulm, Germany |
| Rachna Shroff, MD, MS | University of Arizona Cancer Center, AZ, USA |
| Elizabeth Smyth, MD | Oxford University Hospitals NHS Foundation Trust, Oxford, UK |
| Arndt Vogel, MD, ESMO, ASCO, EASL | Toronto General Hospital and University of Toronto, Canada |
| Rebecca K.S. Wong, MB, ChB, MSc, FRCP | Princess Margaret Cancer Center, University Health Network; Department of Radiation Oncology, University of Toronto, Ontario, Canada |
| Susana Banerjee, FRCP, MBBS, MA, PhD | The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK |
| Elena Ioana Braicu, MD, PhD | Department of Gynecology, Charité University Medicine, Campus Virchow, Berlin, Germany |
| Alexandra Leary, MD, PhD | Gustave Roussy Institute, Université Paris Saclay, GINECO group, France |
| Yeh Chen Lee, MBBS, BMedSci, MPhil[H1], FRACP | Prince of Wales and Royal Hospital for Women, NSW, Australia |
| Rowan Miller, MD, PhD | University College London and St Bartholomew's Hospitals, London UK |
| Natalie Ngoi, MD | Department of Hematology-Oncology, National University Cancer Institute, Singapore |
| Angélica Nogueira Rodrigues, MD, PhD | Federal University of Minas Gerais; Latin American Cooperative Oncology Group, Brazil |
| David O'Malley, MD | Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine (OH, USA) |
| José Pérez-Fidalgo, MD, PhD | Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia (Department of Medicine), Valencia, Spain |
| Bhavana Pothuri, MD, MS | Gynecologic Oncology, NYU Grossman School of Medicine, NYU Langone Health, Laura & Isaac Perlmutter Cancer Center NY, NY, USA |
| Clare Scott, MBBS, PhD | The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia |
| Ronnie Shapira-Frommer, MD | Ella Lemelbaum Institute for Immuno-oncology & Melanoma and the Onco-gynecology service, Sheba Medical Center, Ramat-Gan, Israel |
| Anna Tinker, MD | Division of Medical Oncology, BC Cancer, Vancouver, Canada |
| Rongyu Zang, MD, PhD | Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China |
| Ana Arance, MD, PhD | Department of Medical Oncology, Hospital Clinic Barcelona, Spain |
| Nikhil Khushalani, MD | H. Lee Moffitt Cancer Center & Research Institute, FL, USA |
| Mark Middleton, MD, PhD | Department of Oncology, University of Oxford, Oxford, UK |
| Yana Najjar, MD | Clinical and Translational Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA |
| April Salama, MD | Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, NC, USA |
| Fiona Blackhall, PhD, FRCP | Department of Medical Oncology, The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, UK |
| Wilfried Eberhardt, MD | University Duisburg-Essen, Essen, Germany |
| Daichi Fujimoto, MD, PhD | Internal Medicine III, Wakayama Medical University, Wakayama, Japan |
| Justin Gainor, MD | Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA |
| Marina Garassino, MD | Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL, USA |
| Cesare Gridelli, MD | S.G. Moscati Hospital, Avellino, Italy |
| Lizza Hendriks, MD, PhD | Department of Pulmonary Diseases, Maastricht UMC+, the Netherlands |
| Hidehito Horinouchi, MD, PhD | Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan |
| Ning Li, MD | Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, China |
| Sun Min Lim, MD, PhD | Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea |
| Herbert H. Loong, MBBS, FRCP | Department of Clinical Oncology and Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong |
| Shun Lu, MD, PhD | Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China |
| Laura Mezquita, MD, PhD | Medical Oncology Department, Hospital Clinic of Barcelona; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS; Department of Medicine, University of Barcelona, Spain |
| Jordi Remon, MD, PhD | Department of Medicine Gustave Roussy, Villejuif, France |
| Christian Rolfo, MD, PhD, MBA,Dr.h.c. | The Center of Thoracic Oncology at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA |
| Adrian Sacher, MD | Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada |
| Ming-Sound Tsao, MD, FRCPC | Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada |
| Paul Wheatley-Price, BSc, MD MBChB, FRCP | Department of Medicine, Division of Medical Oncology, University of Ottawa, ON, Canada |
| Antoinette Wozniak, MD, FACP, FASCO | UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA |
| David Chan, MBBS PhD | University of Sydney, Sydney, Australia |
| Barbara Kiesewetter, MD | Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria |
| Melvin Chua, MBBS, FRCR, PhD, FAMS | Department of Head and Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore and Duke-NUS Medical School, Singapore |
| Thorsten Füreder, MD | Department of Medicine I, Division of Oncology, Medical University Vienna, Austria |
| Brigette Ma, MBBS(Hon.), FRACP, FHKCP, FHKAM, MD(CUHK) | State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Hong Kong SAR, China |
| Jun Ma, MD, PhD | Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, China |
| Albiruni Abdul Razak, MB, MRCPI, CCT | Princess Margaret Cancer Centre, Toronto, Canada |
| Matías Chacón, MD | Instituto Alexander Fleming, Buenos Aires, Argentina |
| Tom Wei Wu Chen, MD, PhD | Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan |
| Alessandro Gronchi, MD | Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy |
| Bruno Vincenzi, MD, PhD | University Campus Bio-Medico, Rome, Italy |
| Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD | Peter MacCallum Cancer Centre, Australia |
| Kathleen Boyd, MSc PhD | Health Economics & Health Technology Assessment, School of Health & Wellbeing, University of Glasgow, UK |
| Marc Buyse, ScD, ISCB | International Drug Development Institute (IDDI), and Hasselt University, Belgium |
| Antonio Galvano, PhD | Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy |
| Susan Halabi, PhD | Department of Biostatistics and Bioinformatics, Duke University Medical Center and Duke Cancer Institute, NC, USA |
| Caroline Kelly, MSc, BSc | Cancer Research UK Glasgow Clinical Trials Unit, University of Glasgow, UK |
| Andrew Martin, PhD | NHMRC Clinical Trials Centre, University of Sydney, Australia |
| Xiwen (Simon) Qin, PhD | University of Hong Kong, Hong Kong |
| Bhupendra Rawal, MSc | Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, MA, USA |
| Qian Shi, PhD | Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA |
| Takeharu Yamanaka | Department of Biostatistics, Yokohama City University School of Medicine, Japan |
| Jinqiu (Jacky) Yuan, MPh, PhD | Clinical Research Centre, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China |
| Francesco Agustoni, MD | Fondazione IRCCS Policlinico San Matteo, Pavia, Italy |
| Hamzeh Albaba, MD | Cross Cancer Institute, Alberta, Canada |
| Sandra Danielle Algaze, MD | USC Norris Comprehensive Cancer Center, CA, USA |
| Tomonori Araki, MD, PhD | Department of Gastroenterology and Hepatology, Nagasaki University, Nagasaki, Japan |
| Prof. Fatemeh Ardeshir-Larijani, MD, MSc | Winship Cancer Institute, Emory School of Medicine, GA, USA |
| Ilaria Attili, MD | European Institute of Oncology, Milan, Italy |
| Rita Balsano, MD | IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Italy |
| Holly Barker, PhD | The Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne, Australia |
| Fernando Augusto Batista Campos, MD | Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, SP, Brazil |
| Anthony Bejjani, MD | Division of Hematology/Oncology, VA Greater Los Angeles Health System, Geffen School of Medicine at UCLA, Los Angeles, CA, USA |
| Javier David Benitez Fuentes, MD, MSc | Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain |
| Alice Bernard- Tessier, MD MSc | Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France |
| Christine Bestvina ,MD | The University of Chicago Medicine, Chicago, IL, USA |
| Manali Bhave, MD | Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA |
| Daniel Breadner, MSc MD FRCPC | Division of Medical Oncology, London Regional Cancer Program, London Health Science Center, ON, Canada |
| Massimiliano Cani, MD | University of Turin, San Luigi Hospital, Orbassano, Italy |
| Ciro Celsa, MD, PhD | University of Palermo, Italy |
| Johan Chan, MBBS, FRACP | National Cancer Centre Singapore, Singapore |
| Landon Long Chan, MBChB, MSc, FRCR | The Chinese University of Hong Kong, Hong Kong |
| Chi Leung, CHIANG, MD | LKS Faculty of Medicine, HKU, Hong Kong, China |
| Siu Ching, MBBS | Chinese University of Hong Kong, Hong Kong |
| Niamh Coleman, MD PhD | Department of Medical Oncology, St. James's Hospital, Trinity College, Dublin, Ireland |
| Giuseppe A Colloca, MD | Department of Cure Primarie, UOSD Oncologia Territoriale, AUSL di Bologna, Sasso Marconi, Bologna, Italy |
| Ciara Conduit, FRACP MBBS | Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia |
| Salvatore Corallo, MD | Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy |
| Rena D. Callahan, MD | Santa Clarita Cancer Care, UCLA Health, US |
| Antonio D’Alessio, MD | Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK |
| Michael John Devlin, MD PhD | Barts Cancer Institute, Queen Mary University of London, London, UK |
| Federico Pio Fabrizio, PhD | University of Enna "Kore", Italy |
| Mohammad H. Fard-Aghaie, MD, FACS, FEBS | University Medical Center Hamburg-Eppendorf, Hamburg, Germany |
| Dechao Feng, MD, PhD | University College London, UK |
| Sarah Elizabeth Fenton, MD PhD | Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA |
| Gianluca Ferini, MD | University of Enna Kore, Enna, Italy |
| Vincenzo Fiorentino, MD | University of Messina, Messina, Italy |
| Michael Flynn, MD PhD | Department of Oncology, University College London Hospital, University College London, London, UK |
| Victor Hugo Fonseca de Jesus, MD, MSc | Centro de Pesquisas Oncológicas (CEPON), Brazil |
| Andrea Fung, MD PhD | Department of Oncology, Queen's University, Kingston, ON, Canada |
| Miguel Garcia-Pardo, MD | Hospital Universitario Ramón y Cajal, Madrid, Spain |
| Ana C. Garrido-Castro, MD | Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA |
| Amanda N. Goldin, MD | Department of Orthopaedic Surgery, University of California, Irvine, CA, USA |
| Rodrigo Gomes Taboada, MD, MSc | A.C.Camargo Cancer Center, São Paulo, SP, Brazil |
| Martín Igor Gómez-Randulfe Rodríguez, MD | The Christie NHS Foundation Trust, UK |
| Rachel Goodwin, MD, MSc, FRCPC | Department of Medicine, The Ottawa Hospital Cancer Centre, Ontario, Canada |
| Mohamed Gouda, MD, MSc | The University of Texas MD Anderson Cancer Center, Houston, United States |
| Juan Francisco Grau-Béjar, MD MSc | Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain |
| Gwo Yaw Ho, BSc (HON), MBChB, FRACP, PhD | Monash University and Monash Health, Austraila |
| Anis Hamid, MBBS | Memorial Sloan Kettering Cancer Center, NY, USA |
| Diana L Hanna, MD | USC Norris Comprehensive Cancer Center, CA, USA |
| Helen Hockings,MB BChir PhD | St Bartholomew's Hospital, London, UK |
| Jason Chia-Hsun Hsieh, M.D., M.Sc, Ph.D. | Chang Gung Memorial Hospital at Linkou, Taiwan |
| Robert Hsu, MD, MS | University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, CA, USA |
| Hui-Yao Huang, PhD | Department of Clinical Trials Center, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China |
| Laura Huppert, MD | UCSF Helen Diller Family Comprehensive Cancer Center, USA |
| Gino K. In, MD MPH | University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Division of Oncology, Los Angeles, CA, USA |
| Giuseppe Carlo Iorio, MD | Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy |
| Di (Maria) Jiang, MD MSc FRCPC | Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada |
| Lawrence Kasherman, BMed MMed (ClinEpi) FRACP | Illawarra Cancer Care Centre, Wollongong Hospital and Concord Clinical School, University of Sydney, NSW, Australia |
| Lucy Boyce Kennedy, MD | The Cleveland Clinic Foundation, Cleveland, OH, USA |
| Hyung-Don Kim, MD, PhD | Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea |
| Susanne Klein-Scory, PhD | Department of Medicine, Knappschaft Kliniken Universitätsklinikum Bochum, Ruhr University of Bochum, Germany |
| Yoshiyasu Kono, MD, PhD | Department of Gastroenterology and Hepatology, Okayama University, Okayama City, Okayama, Japan |
| Edmond Kwan, MBBS FRACP PhD | Vancouver Prostate Centre, Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada |
| Ruth Lauren Sacks, MD | Emory University School of Medicine, USA |
| Jieun Lee, MD PhD | Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea |
| Jii Bum Lee, MD | Yonsei Cancer Center, Yonsei University College of Medicine, South Korea |
| Kyung-Hun Lee, MD PhD | Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, Seoul, South Korea |
| Nathalie LeVasseur, MD, FRCPC | Department of Medical Oncology, BC Cancer, Vancouver, Canada |
| Kunyu Li, PhD | Department of Pathology, University of Otago, Dunedin, New Zealand |
| Pedro Emanuel Rubini Liedke, MD MSc | Oncoclinicas Porto Alegre and Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil |
| Jasmine Lim, BSc DPhil | Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia |
| Jessica J. Lin, MD | Department of Medicine, Massachusetts General Hospital, Boston, MA, USA |
| Marla Lipsyc-Sharf, MD | Department of Medicine, Dana-Farber Cancer Institute/Mass General Brigham, MA, USA |
| Wen-Yang Liu, MD | Chinese Academy of Medical Sciences and Peking Union Medical College, China |
| Fernando López-Campos, MD PhD MSc | Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain |
| Sara López-Tarruella, MD PhD | Medical Oncology Department, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERONC, Geicam, Universidad Complutense, Madrid, Spain |
| Lucy Ma, MD | Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada |
| Florit Marcuse, MD PhD | Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, Maastricht, Netherlands |
| Antonio Marra, MD MSc | Early Drug Development for Innovative Therapies, European Institute of Oncology IRCSS, Milan, Italy |
| Corinne Maurice-Dror, MD | BC Cancer, Vancouver, BC, Canada |
| Marcel Mayer, MD, MHBA | University Hospital Cologne, Cologne, Germany |
| Arielle J Medford, MD | Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA |
| Rebeca Lozano Mejorada, MD, PhD | Medical Oncology Department, Complejo Asistencial Universitario Salamanca, Salamanca, Spain |
| Alessandra Merlini, MD, PhD | University of Turin, Orbassano (TO), Italy |
| Kenji Morimoto, MD, PhD | Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan |
| Izuma Nakayama, MD, PhD | Department of Gastrointestinal Chemotherapy National Cancer Center Hospital East, Kashiwa, Japan |
| Fabiana Napolitano, MD, PhD | Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX |
| Romario Nguyen, PhD | Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney and Westmead Hospital, NSW, Australia |
| Hirofumi Ohmura, MD, PhD | Kyushu University, Fukuoka, Japan |
| Marina Pacheco Rovira, MD | Department of Pathology, Ciudad de La Salud CSS, Panama, Panama |
| Angelica Petrillo, MD | Medical Oncology Unit, Ospedale del Mare, Napoli, Italy |
| Quincy SC Chu, MD, FRCPC | University of Alberta, Canada |
| Tomás Reinert, MD PhD | Breast Medical Oncology Department - Oncoclinicas – Porto Alegre, Brazil |
| Dae-Gon Ryu, MD, PhD | Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea |
| Daniel S. Childs, MD | Mayo Clinic, Rochester, MN, USA |
| Francesco Sabbatino, M.D., Ph.D | University of Salerno, Italy |
| Tahlia Scheinberg, MBBS (Hons 1) FRACP | Medical Oncology, Chris O’Brien Lifehouse, Camperdown, NSW, Australia |
| Sandor Schokker, MD PhD | Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands |
| J. Eva Selfridge, MD, PhD | University Hospitals Seidman Cancer Center, Ohio, US; Case Comprehensive Cancer Center, Ohio, US |
| Michael Shafique, MD | Moffitt Cancer Center-USF, Florida, USA |
| Jie Shen, PhD | University of Virginia, USA |
| Demetria Smith-Graziani, MD, MPH | Winship Cancer Institute of Emory University, USA |
| Alannah Smrke, MD | Department of Medical Oncology, BC Cancer, Vancouver, Canada |
| Yung-Yeh Su, MD, PhD | National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan |
| James Symanowski, PhD | Atrium Health Levine Cancer, USA |
| Tira Tan, MBBS MRCP | Division of Medical Oncology, National Cancer Centre Singapore, Singapore |
| Huarong Tang, MD | Department of Gynecological Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, China |
| Jacob Thomas, MD | USC Norris Comprehensive Cancer Center, California, US |
| Consuelo Torrini, PhD | Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA |
| Erica Tsang, MD MPH FRCPC | Princess Margaret Cancer Centre, Toronto, Canada |
| Ilit Turgeman, MD | Carmel Medical Center, Haifa, Israel |
| Robin van Geel, PharmD, PhD | Maastricht University Medical Centre, Maastricht, Netherlands |
| David VanDerWeele, MD PhD | Hematology and Oncology, Northwestern University Feinberg School of Medicine and OncoSET Precision Oncology Program, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA |
| Dawei Wu | Clinical Trials Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, China |
| Li Xie, M.D, Ph.D | Shanghai Jiao Tong University School of Medicine, China |
| Eun-mi Yu, MD | Inova Health System, VA, USA |
| Irene Yu, MD | BC Cancer Surrey, Surrey, BC, Canada |
| Yongfeng Yu, MD PhD | Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China |
| Bingnan Zhang, MD | Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, TX, USA |
| Jian-Guo Zhou, MD, PhD | The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China |
| Hongcheng Zhu, MD,PhD | Fudan University Shanghai Cancer Center, Shanghai, China |
Manuscript Submission Guidelines: Therapeutic Advances in Medical Oncology
- Open Access
- Article fee
- Article Types
- Editorial policies
4.1 Peer Review Policy
4.2 Authorship
4.3 Acknowledgements
4.4 Funding
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
4.9 Data - Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement - Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services - Submitting your manuscript
7.1 ORCID
7.2 Information required for completing your submission
7.3 Corresponding author contact details
7.4 Permissions - On acceptance and publication
8.1 SAGE Production
8.2 Continuous publication
8.3 Promoting your article - Further information
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site http://mc.manuscriptcentral.com/tao to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Medical Oncology will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.
Unsolicited manuscripts submitted to Therapeutic Advances in Medical Oncology are subject to an Article Processing Charge (APC) of 2,000 USD (+VAT where applicable*) payable upon acceptance. These articles will be published under a Creative Commons Licence and will be made openly available.
*If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.
Therapeutic Advances in Medical Oncology considers the following kinds of article for publication:
- Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature).
- Review Articles. These manuscripts are usually commissioned by the Editors, but the following types of high-quality review will be considered:
(a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal;
(b) Perspective reviews – review articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic;
(c) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy. - Systematic Reviews. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).
- Meta-analyses. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).
- Case Reports. These structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care.
- Case Series. These descriptive structured reports (which do not involve formal hypotheses or pre-specified methodology or analyses) of a small group of patients should include a full review of the pertinent literature and a section on implications for clinical care.
- Study Protocols. These can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.
- Letters to the Editor. These brief opinion pieces should be as concise as possible, usually no more than 1000 words.
The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Medical Oncology welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.
The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Medical Oncology operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author. Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations. All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.
As part of the submission process you will be asked to provide the names of 3 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
-
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).
Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
-
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Therapeutic Advances in Medical Oncology requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
4.5 Declaration of conflicting interests
It is the policy of Therapeutic Advances in Medical Oncology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
4.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
Therapeutic Advances in Medical Oncology endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
Therapeutic Advances in Medical Oncology encourages all authors to submit any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at oncology@sagepub.co.uk
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
5.1.1 Plagiarism
Therapeutic Advances in Medical Oncology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
5.2 Contributor's publishing agreement
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Therapeutic Advances in Medical Oncology publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
6.2 Artwork, figures and other graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Therapeutic Advances in Medical Oncology adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.
6.5 English language editing services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Therapeutic Advances in Medical Oncology is hosted on SAGE Track, a web-based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/tao to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.
We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.
7.2 Information required for completing your submission
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
7.3 Corresponding author contact details
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway
8. On acceptance and publication
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been sent to SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Therapeutic Advances in Medical Oncology editorial office as follows:
For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:
Commercial Sales Team, London, UK Tel: +44 20 7336 1205 Email: reprints@sagepub.co.uk